For comprehensive information about Parkinson’s diagnosis please visit the EPDA website.
European Union announces new programme to improve Parkinson’s diagnosis
Author: Parkinson's Life editorsPublished: 17 January 2018
Prep: Cook: Serves:
The European Union has announced the launch of the Magnetic Diagnostic Assay for Neurodegenerative Diseases (MADIA) – a project with the ultimate goal of improving diagnosis for those living with Parkinson’s and Alzheimer’s.
The project, which is in partnership with a range of international universities and institutions, will focus on the development of a novel device that will help clinicians perform a simple click and analysis to diagnose both conditions.
Dr Francisco Campos, of the Clinical Neurosciences Research Laboratory, said: “An early diagnosis is crucial to maximise the effectiveness of the treatments in order to mitigate the devastating effects of these illnesses and slow disease progression.
“MADIA is funded by the European Union’s Horizon 2020 research and innovation programme, and consists of a multitasking team with more than 50 professionals in the fields of biology, physics and engineering.”
Share this story
Parkinson’s podcast: L-dopa – waiting for the next act
Discussion: Why has it taken so long to improve levodopa delivery?READ MORE
Personalised and on-the-spot therapy: deep brain stimulation
Boston Scientific’s Vercise deep brain stimulation systemREAD MORE
Highlights: Cycle Vietnam to Cambodia and NBA All-Star weekendREAD MORE